Literature DB >> 21128245

Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.

Judith Ertle1, Alexander Dechêne, Jan-Peter Sowa, Volker Penndorf, Kerstin Herzer, Gernot Kaiser, Jörg F Schlaak, Guido Gerken, Wing-Kin Syn, Ali Canbay.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in developed countries, and accumulating evidence suggests it as the hepatic manifestation of the metabolic syndrome (MS). Although the published prevalence of hepatocellular carcinoma (HCC) is low in NAFLD/NASH patients, most of these data have been derived from areas endemic for viral hepatitis. We recruited 162 adults with HCC between February 2007 and March 2008, investigated the underlying etiologies and determined the prevalence of the MS and related features within each group. Patients with NAFLD/NASH-associated HCC exhibited a higher prevalence of metabolic features (Type 2 diabetes mellitus, hypertension, dyslipidemia, coronary artery disease) compared to non-NAFLD/NASH-HCC. Intriguingly, a significant number (41.7%; p < 0.005) of individuals with NAFLD/NASH-HCC had no evidence of cirrhosis. Patients with alcohol-induced liver disease also displayed many features (14/19, 73.7%) of the MS, although, in contrast to NAFLD/NASH-HCC, alcohol-associated HCC was highly associated with cirrhosis (95.0%; p = 0.064). NAFLD/NASH as the hepatic entity of the MS may itself pose a risk factor for HCC, even in the absence of cirrhosis. The MS may also promote development of HCC among those with alcoholic liver disease. Increased awareness of liver manifestations in the MS may instigate early interventions against developing HCC.
Copyright © 2010 UICC.

Entities:  

Mesh:

Year:  2011        PMID: 21128245     DOI: 10.1002/ijc.25797

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  169 in total

1.  Signal profile on Gd-EOB-DTPA-enhanced MR imaging in non-alcoholic steatohepatitis and liver cirrhosis induced in rats: correlation with transporter expression.

Authors:  Natsuko Tsuda; Osamu Matsui
Journal:  Eur Radiol       Date:  2011-08-11       Impact factor: 5.315

2.  Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer.

Authors:  M Walker; H B El-Serag; Y Sada; S Mittal; J Ying; Z Duan; P Richardson; J A Davila; F Kanwal
Journal:  Aliment Pharmacol Ther       Date:  2016-01-19       Impact factor: 8.171

3.  A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma.

Authors:  Divya P Kumar; Prasanna K Santhekadur; Mulugeta Seneshaw; Faridoddin Mirshahi; Cora Uram-Tuculescu; Arun J Sanyal
Journal:  Hepatology       Date:  2019-03-04       Impact factor: 17.425

Review 4.  Hepatic glucose sensing and integrative pathways in the liver.

Authors:  Maaike H Oosterveer; Kristina Schoonjans
Journal:  Cell Mol Life Sci       Date:  2013-11-07       Impact factor: 9.261

5.  Hepatocellular carcinoma disguised as liver abscesses.

Authors:  Jasmine Gowarty; Arshad Ghauri; George Martinez; Angela L Birdwell
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-03-20

6.  Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation.

Authors:  A Wree; C D Johnson; J Font-Burgada; A Eguchi; D Povero; M Karin; A E Feldstein
Journal:  Cell Death Differ       Date:  2015-04-24       Impact factor: 15.828

Review 7.  NAFLD/NASH in patients with type 2 diabetes and related treatment options.

Authors:  M G Radaelli; F Martucci; S Perra; S Accornero; G Castoldi; G Lattuada; G Manzoni; G Perseghin
Journal:  J Endocrinol Invest       Date:  2017-11-30       Impact factor: 4.256

8.  Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults.

Authors:  Yvonne N Flores; Rafael Velázquez-Cruz; Paula Ramírez; Manuel Bañuelos; Zuo-Feng Zhang; Hal F Yee; Shen-Chih Chang; Samuel Canizales-Quinteros; Manuel Quiterio; Guillermo Cabrera-Alvarez; Nelly Patiño; Jorge Salmerón
Journal:  Mol Biol Rep       Date:  2016-10-17       Impact factor: 2.316

9.  Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.

Authors:  Scott M Thompson; Ishan Garg; Eric C Ehman; Shannon P Sheedy; Candice A Bookwalter; Rickey E Carter; Lewis R Roberts; Sudhakar K Venkatesh
Journal:  Br J Radiol       Date:  2018-08-29       Impact factor: 3.039

10.  Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Srikar Mapakshi; Yamini Natarajan; Maneerat Chayanupatkul; Peter A Richardson; Liang Li; Roxanne Desiderio; Aaron P Thrift; Steven M Asch; Jinna Chu; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.